Advertisement

Topics

Bonti Announces Start of LANTERN-1 Phase 2 Clinical Study Evaluating EB-001 in Reducing Musculoskeletal Pain

08:11 EDT 23 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Interim Data Anticipated by Year-end 2017 Bonti, a privately-held, clinical-stage biotechnology company, today announced the initiation of its LANTERN clinical program aimed at relieving musculoskeletal pain and reducing use...

Other Sources for this Article

Bonti
Orlando Rodrigues
Media Relations
760-212-5727
orlando@bonti.com

NEXT ARTICLE

More From BioPortfolio on "Bonti Announces Start of LANTERN-1 Phase 2 Clinical Study Evaluating EB-001 in Reducing Musculoskeletal Pain"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...